Cantai Therapeutics
PrivateLast Round
Seed
Nov 20, 2023
Company Overview
Cantai Therapeutics is a biotechnology company that develops cytokine-targeting bispecific antibodies for the treatment of autoimmune and inflammatory disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cantai Therapeutics Comparables
Compare Cantai Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Dualitas Therapeutics | 86% | |
| Navigator Medicines | 86% | |
| Ypsilon Therapeutics | 79% | |
Cantai Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 20, 2023 |
Cantai Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Seed |
| Tellus BioVentures | Seed |
| 82VS | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 20, 2023
Led by 82VS and Agent Capital.
Cantai Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Cantai Therapeutics's valuation, stock price, and market status.